← Eichor
Study identifier: NCT06428448 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections

Condition: Periprosthetic Joint Infection  ·  Sponsor: OsteoRemedies, LLC

PhasePhase 2
Planned participants60
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersYes

About this study

This study is being conducted to evaluate the safety and effectiveness of the REMEDY SPECTRUM IM Spacer Nail in the treatment of ankle-related infections. The study is expected to take approximately 18 months from first subject enrolled to the last follow-up visit. It will have a 12-month enrollment period and a 6-month follow-up. This study is a Prospective, multicenter, single-arm clinical trial. All subjects enrolled in this study will receive the REMEDY SPECTRUM IM Spacer Nail.

This description comes directly from the study's public registry record.

Talk to the study team

Crystal Djaba  ·  470-736-7850  ·  cdjaba@mcra.com

Jacob Schafer  ·  jschafer@mcra.com

Always discuss trial participation with your own doctor first.

Locations (3)

University of Michigan Health - Sparrow Clinical Research InstituteLansing, Michigan, United StatesRecruiting
OrthoCarolina Research InstituteCharlotte, North Carolina, United StatesRecruiting
Duke University Medical CenterDurham, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06428448